Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Leuk Lymphoma. 2016 May 17;57(10):2409–2416. doi: 10.3109/10428194.2016.1161186

Figure 1A and B. Tris-DBA induces apoptosis in CLL B-cells.

Figure 1A and B

Primary CLL B-cells characterized as either mutated IgVH (n=7) or unmutated IgVH (n=6) in serum-free AIM-V medium or normal PBMC in RPMI were treated with increasing doses of Tris-DBA (2.5–10 μM) for 24 h. At the indicated time, cells were harvested, stained with annexin V/PI, and analyzed by flow cytometry for viability. The apoptosis levels for PBMC were subdivided based on two color flow for annexin V and reactivity for either CD3 (T-cells), CD19 (B-cells) or CD16 (NK cells).